Compare CHRN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHRN | ARQT |
|---|---|---|
| Founded | 2026 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.2B |
| IPO Year | 2012 | 2020 |
| Metric | CHRN | ARQT |
|---|---|---|
| Price | $15.28 | $28.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $38.38 |
| AVG Volume (30 Days) | 120.6K | ★ 2.9M |
| Earning Date | 10-14-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.67 | 88.79 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $84.77 | $43.01 |
| Revenue Next Year | $603.10 | $27.70 |
| P/E Ratio | ★ N/A | $970.00 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $12.62 | $19.30 |
| 52 Week High | $30.00 | $31.77 |
| Indicator | CHRN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 34.10 | 62.77 |
| Support Level | N/A | $24.91 |
| Resistance Level | $22.29 | $30.30 |
| Average True Range (ATR) | 1.57 | 1.20 |
| MACD | -0.44 | 0.32 |
| Stochastic Oscillator | 30.01 | 84.07 |
ChronoScale Holdings Corp is providing cloud services to customers at third-party colocation centers located in Colorado, Minnesota and Utah, such as artificial intelligence and machine learning developers, seeking to develop their products. It design, develop, and market exoskeleton and complementary products that augment human strength, endurance, and mobility. Its Cloud Business provides graphics processing unit (GPU) computing solutions that enable customers to execute critical workloads related to artificial intelligence (AI), machine learning (ML), rendering, and other High Performance Computing (HPC) tasks at scale in a capacity-constrained market. It has one operating segment Cloud Business.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.